Matthew Milowsky, MD, FASCO (IMAGE)

University of North Carolina Health Care

Matthew Milowsky, MD, FASCO

Caption

The promise of incorporating new treatments and predictive biomarkers to select the right patient for the right treatment every time offers a bright future for bladder cancer patients. “The goal is to provide treatment only to those who need it,” said Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center. “By using predictive biomarkers, we can focus on patients most likely to benefit from additional therapy while sparing others from unnecessary side effects.”

Credit

UNC Lineberger Comprehensive Cancer Center

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.